DYN

Dyne Therapeutics, Inc. DYN

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-178.56M

Quarter to Jun 30

Free cash flow

$-131.80M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$4.23B total
T. Rowe Price Investment Management, Inc.
$686.56M+0.4%
BlackRock, Inc.
$275.50M+6.0%
Jupiter Topco LLC
$266.63M--
FMR LLC
$248.91M+25.8%
STATE STREET CORP
$165.65M+12.1%
Orbis Allan Gray Ltd
$155.62M+3.6%
Atlas Venture Life Science Advisors, LLC
$151.03M-25.5%
VANGUARD CAPITAL MANAGEMENT LLC
$140.17M-1.5%
TCG Crossover Management, LLC
$102.50M0.0%
VANGUARD PORTFOLIO MANAGEMENT LLC
$89.92M-2.7%
PRICE T ROWE ASSOCIATES INC /MD/
$87.44M+69.1%
FCPM III SERVICES B.V.
$85.47M-17.1%
GEODE CAPITAL MANAGEMENT, LLC
$83.16M+6.8%
Vestal Point Capital, LP
$74.96M-15.6%
ORBIMED ADVISORS LLC
$71.86M+10.9%
Frazier Life Sciences Management, L.P.
$70.03M0.0%
ARMISTICE CAPITAL, LLC
$68.57M-2.8%
JPMORGAN CHASE & CO
$67.15M-3.1%
PERCEPTIVE ADVISORS LLC
$59.73M-42.4%
Logos Global Management LP
$56.64M+82.1%
BANK OF AMERICA CORP /DE/
$49.60M+54.7%
VR Adviser, LLC
$48.28M0.0%
GOLDMAN SACHS GROUP INC
$47.91M+25.2%
Siren, L.L.C.
$47.29M-4.5%
FRANKLIN RESOURCES INC
$45.10M+1.1%
See all 246 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/DYN

Earnings Per Share

13fpro.ai/company/DYN

Loading ratio trend…

DYN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Dyne Therapeutics, Inc. (DYN): stock profile, AI score and financials

Dyne Therapeutics, Inc. (DYN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. DYN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Dyne Therapeutics, Inc. reports net income of $-178.6M, free cash flow of $-131.8M. Top institutional holders of DYN by reported 13-F value include T. Rowe Price Investment Management, BlackRock, Jupiter Topco, based on the most recent SEC filings. DYN trades on the Nasdaq exchange and files with the SEC under CIK 1818794. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DYN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dyne Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1818794 →